Products
Online Inquiry
Crizotinib
Cat. No.:
0225LY-0503
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Crizotinib is an ATP-competitive, small-molecule inhibitor that targets the tyrosine kinase receptors ALK (IC50 = 20 nM) and c-MET (IC50 = 8 nM).
Synonym:
PF-02341066; 877399-52-5; (R)-crizotinib; (R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine; 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine; 3-[(R)-1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
CAS No.:
877399-52-5
Compound CID:
11626560
Formula:
C21H22Cl2FN5O
Formula Weight:
450.34
Specification
Targets&IC50:
ALK: 24 nM (cell free); c-Met: 11 nM (A498 cells)
Relative Density:
1.475 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Crizotinib can be used in precision oncology research focusing on ALK and ROS1 tyrosine kinase signaling in non-small cell lung cancer.
Library Information
Target:
ALK; c-Met
Receptor:
ALK; c-Met/HGFR
Pathways:
Angiogenesis; Tyrosine kinase/adaptors; Immunology/Inflammation; Autophagy
Plate Number:
AOCL-7
Plate Location:
e5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
34.5 mg/mL; 76.61 mM
